- Statement of Changes in Beneficial Ownership (4)
August 01 2012 - 10:53AM
Edgar (US Regulatory)
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Parker Craig C
|
2. Issuer Name
and
Ticker or Trading Symbol
HUMAN GENOME SCIENCES INC
[
HGSI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Sr VP Strategy and Corporate D
|
(Last)
(First)
(Middle)
14200 SHADY GROVE ROAD
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/30/2012
|
(Street)
ROCKVILLE, MD 20850
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Employee Stock Option - Right to Buy
|
$8.2300
|
7/30/2012
|
|
D
|
|
|
54000.0000
|
(1)
|
3/10/2022
|
Common Stock
|
54000.0000
|
$14.2500
|
0.0000
|
D
|
|
Explanation of Responses:
|
(
1)
|
This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $325,080.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Parker Craig C
14200 SHADY GROVE ROAD
ROCKVILLE, MD 20850
|
|
|
Sr VP Strategy and Corporate D
|
|
Signatures
|
/s/James H. Davis (Power of Attorney) on behalf of
|
|
8/1/2012
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Human Genome Sciences, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles